After Hours Gainers:
Companies trading higher in after hours in reaction to earnings: PLAY +9.3%, KFY +0.9%, TIVO +0.2%
Companies trading higher in after hours in reaction to news: AKBA +65.2% (announced positive top-line results from its Phase 2 study of vadadustat in dialysis patients with anemia related to chronic kidney disease), VTAE +29.6% (announced positive top-line results from initial phase 1 study of first-in-class RORyt Inhibitor VTP-43742 in autoimmune disorders), CLR +1.6% (announced plans to reduce its 2015 capital budget by $300-350 million more than previously approved)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: PSUN -16.7%, FCEL -9.2%, MW -6.1%, PBY -3.9%, CLLS -0.9%
Companies trading lower in after hours in reaction to news: TTPH -77.8% (announced eravacycline did not achieve primary endpoint in pivotal portion of complicated urinary tract infections Trial), ZQK -60.4% (Bloomberg reporting co will prepare a bankruptcy filing), FLXN -41.4% (reported top-line data from pivotal phase 2b clinical trial for FX006 in patients with moderate to severe osteoarthritis (OA) knee pain; primary endpoint of study not met), AQXP -5.9% (announced proposed public offering of $75 million of common stock), CMRX -5.2% (provided clinical development update for Brincidofovir, stating that SUPPRESS data continues to be expected in early 2016), FPRX -3.4% (initiated patient dosing in its Phase 1a/1b clinical trial, evaluating the immunotherapy combination of FPA008 with Opdivo), UAL -1.7% (named Oscar Munoz as President and CEO; announced that its executive vice president of communications and government affairs and its senior vice president of corporate and government affairs have stepped down), DY -1.7% (announced a private placement offering of $400 mln in convertible senior notes due 2021; authorizes the repurchase of up to $75 million of its common stock)
After losing 3.4% last week, the restless stock market began the holiday-shortened week with a broad-based surge. The Nasdaq Composite led the way, spiking 2.7% while the S&P 500 jumped 2.5% with the bulk of the advance taking place at the opening bell.
The buying surge at the start reflected a build-up of strength in the futures market that took root yesterday as U.S. futures labored their way higher alongside European equities. Once the Tuesday session began in Asia, China's Shanghai Composite rallied 2.9% with speculation of continued state support for equities overshadowing mediocre trade data (trade balance $60.24 billion; expected $48.20 billion) that showed a 5.5% year-over- year decline in exports (expected -6.0%) and a 13.8% drop in imports (expected -8.2%; prior -8.1%).
The late-afternoon gains in China stirred up overall risk tolerance, leading to more gains in the U.S. futures market while European equities enjoyed an opening surge. Better than expected economic data highlighted the European session as eurozone Q2 GDP was unexpectedly revised up to 0.4% quarter-over-quarter from 0.3%.
Once the U.S. cash market opened, equity indices spiked, hovering not far below their highs into the afternoon. All ten sectors contributed to the opening move higher, but daylong strength in heavily-weighted groups like technology (+2.8%), industrials (+2.8%), financials (+2.6%), and health care (+2.8%) kept the market from drifting too far away from its early high. The strength in those areas proved supportive in the late afternoon as the market charged to a fresh high during the last two hours of the session.
Despite the big push higher, today's trading volume was a bit below recent averages. That said, a final buying surge brought the NYSE floor total up to 898.5 million shares versus the 20-day average of 984 million.
The top-weighted technology sector was a clear outperformer at the start and the group remained among the leaders into the close. High-beta chipmakers rallied broadly with the PHLX Semiconductor Index surging 4.4% back to levels seen in mid-August. All 30 index components posted solid gains, but the spotlight was on Microchip (MCHP 44.86, +3.86), which spiked 9.4% after the company raised its guidance.
Similar to chipmakers, the high-beta biotechnology group enjoyed all-around strength, sending the iShares Nasdaq Biotechnology ETF (IBB 351.77, +14.67) higher by 4.4%. The biotech ETF climbed above its 200-day moving average (345.04) and helped the Nasdaq stay ahead of the broader market throughout the session.
With more than 2400 NYSE-listed issues ending the day with gains versus 650 decliners, green hues dominated most stock screens. Even the energy sector (+1.5%) was able to end the day well above its flat line even as crude oil futures shed 0.3%, slipping to $45.94/bbl.
Today's advance in equities lured some money out of the Treasury market as the 10-yr note retreated into the afternoon, settling near its low with the benchmark yield up seven basis points at 2.19%.
Investors received just one economic report today, which was met with little fanfare. The Consumer Credit report for July showed an increase of $19.10 billion, which was higher than the consensus estimate of $18.00 billion. The prior month's credit growth was revised to $27.00 billion from $20.70 billion.
Tomorrow's economic data will be limited to the 7:00 ET release of the weekly MBA Mortgage Index and the July Job Openings and Labor Turnover Survey, which will be reported at 10:00 ET.
- Nasdaq Composite +1.6% YTD
- Russell 2000 -3.5% YTD
- S&P 500 -4.4% YTD
- Dow Jones Industrial Average -7.5% YTD
(New York Times) -- Mylan’s $28 billion tender offer for its rival Perrigo, which starts next week, isn’t good enough.The hostile bid by Mylan, a Dutch generic drug firm, for Perrigo, an over-the-counter medicine maker based in Ireland, carries a stingy premium and comes mostly in paper. Perrigo’s owners don’t need to swap stock in a shareholder-unfriendly company with bad governance and financial risk when an auction might generate a better result.Perrigo’s investors may be tempted to take what they can get. But under scrutiny, the offer looks less compelling, starting with just a 14 percent control premium. Mylan has done a respectable job over the last decade, with 300 percent shareholder returns. Perrigo has risen more than tenfold. Perrigo’s business of making store-brand over-the counter medicines has better prospects than Mylan’s business of making generic pills. Analysts expect it to grow more than twice as fast in coming years.Since moving its headquarters to the Netherlands, Mylan hasn’t been obviously run for the benefit of shareholders. This summer, Teva wanted to buy the firm for more than $80 a share. Rather than accept this mouthwatering price, the board and an independent company foundation exercised a poison pill that sent its suitor scurrying away. Mylan now trades at about $48. The company’s legal address in the Netherlands also makes it hard to replace directors. Its proxy statements contain a thicket of related-party transactions.There’s some risk for Perrigo shareholders in voting against the deal. Perrigo shares are trading about 11 percent above where they were before Mylan’s arrival, while the Standard & Poor’s 500-stock index has fallen about 8 percent. This premium and perhaps more might disappear if shareholders opt for independence.Worse, Mylan needs 80 percent of the vote to squeeze out minorities under Irish law. If more than half but less than 80 percent take up the offer, it would leave Mylan engorged with debt, and an awkward listed subsidiary. Mylan has even threatened to delist Perrigo shares if this happens. The risk is that Perrigo’s growth slows and its minority shareholders are ignored.Perrigo’s board is confident that the record of two companies will persuade investors to dismiss Mylan’s offer. Overconfidence, however, raises the risk that Mylan will succeed, but not achieve 80 percent of the vote. Perrigo could sidestep this risk, and perhaps fetch a better premium, by auctioning itself off.